keyword
MENU ▼
Read by QxMD icon Read
search

CIBMTR

keyword
https://www.readbyqxmd.com/read/29758108/comparison-of-transplant-specific-prognostic-scoring-systems-in-haploidentical-transplantation-for-myelodysplastic-syndrome
#1
Seung-Hwan Shin, Young-Woo Jeon, Jae-Ho Yoon, Seung-Ah Yahng, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Seok Lee, Hee-Je Kim, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong-Wook Lee, Woo-Sung Min, Yoo-Jin Kim
OBJECTIVES: We intended to identify the predictive abilities of recently published transplant-specific prognostic scoring systems in myelodysplastic syndrome (MDS) patients receiving haploidentical transplantation. METHODS: The outcomes of 73 MDS patients receiving haploidentical transplantation were analyzed, according to the MTPSS, the TRI, and the CIBMTR scoring systems. RESULTS: The median age of patients at transplantation was 50 (range, 19-69) years...
May 14, 2018: European Journal of Haematology
https://www.readbyqxmd.com/read/29685953/outcomes-of-medicare-age-eligible-nhl-patients-receiving-ric-allogeneic-transplantation-a-cibmtr-analysis
#2
Nirav N Shah, Kwang Woo Ahn, Carlos Litovich, Timothy S Fenske, Sairah Ahmed, Minoo Battiwalla, Nelli Bejanyan, Parastoo B Dahi, Javier Bolaños-Meade, Andy I Chen, Stefan O Ciurea, Veronika Bachanova, Zachariah DeFilipp, Narendranath Epperla, Nosha Farhadfar, Alex F Herrera, Bradley M Haverkos, Leona Holmberg, Nasheed M Hossain, Mohamed A Kharfan-Dabaja, Vaishalee P Kenkre, Hillard M Lazarus, Hemant S Murthy, Taiga Nishihori, Andrew R Rezvani, Anita D'Souza, Bipin N Savani, Matthew L Ulrickson, Edmund K Waller, Anna Sureda, Sonali M Smith, Mehdi Hamadani
The application of allogeneic hematopoietic cell transplantation (allo-HCT) in non-Hodgkin lymphoma (NHL) patients ≥65 years in the United States is limited by lack of Medicare coverage for this indication. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we report allo-HCT outcomes of NHL patients aged ≥65 years (older cohort; n = 446) compared with a cohort of younger NHL patients aged 55-64 years (n = 1183). We identified 1629 NHL patients undergoing a first reduced-intensity conditioning (RIC) or nonmyeloablative conditioning allo-HCT from 2008 to 2015 in the United States...
April 24, 2018: Blood Advances
https://www.readbyqxmd.com/read/29567340/country-level-macroeconomic-indicators-predict-early-post-allogeneic-hematopoietic-cell-transplantation-survival-in-acute-lymphoblastic-leukemia-a-cibmtr-analysis
#3
William A Wood, Ruta Brazauskas, Zhen-Huan Hu, Hisham Abdel-Azim, Ibrahim A Ahmed, Mahmoud Aljurf, Sherif Badawy, Amer Beitinjaneh, Biju George, David Buchbinder, Jan Cerny, Laurence Dedeken, Miguel Angel Diaz, Cesar O Freytes, Siddhartha Ganguly, Usama Gergis, David Gomez Almaguer, Ashish Gupta, Gregory Hale, Shahrukh K Hashmi, Yoshihiro Inamoto, Rammurti T Kamble, Kehinde Adekola, Tamila Kindwall-Keller, Jennifer Knight, Lalit Kumar, Yachiyo Kuwatsuka, Jason Law, Hillard M Lazarus, Charles LeMaistre, Richard F Olsson, Michael A Pulsipher, Bipin N Savani, Kirk R Schultz, Ayman A Saad, Matthew Seftel, Sachiko Seo, Thomas C Shea, Amir Steinberg, Keith Sullivan, David Szwajcer, Baldeep Wirk, Jean Yared, Agnes Yong, Jignesh Dalal, Theresa Hahn, Nandita Khera, Carmem Bonfim, Yoshiko Atsuta, Wael Saber
BACKGROUND: For patients with acute lymphoblastic leukemia (ALL), allogeneic hematopoietic cell transplantation (alloHCT) offers potential cure. Life-threatening complications can arise from alloHCT that require the application of sophisticated health care delivery. The impact of country-level economic conditions upon post-transplant outcomes is not known. Our objective was to assess whether these variables were associated with outcomes for patients transplanted for ALL. METHODS: Using data from the Center for Blood and Marrow Transplant Research (CIBMTR), we included 11,261 patients who received a first alloHCT for ALL from 303 centers across 38 countries between the years of 2005 and 2013...
March 19, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29556119/deep-reinforcement-learning-for-dynamic-treatment-regimes-on-medical-registry-data
#4
Ying Liu, Brent Logan, Ning Liu, Zhiyuan Xu, Jian Tang, Yanzhi Wang
In this paper, we propose the first deep reinforcement learning framework to estimate the optimal Dynamic Treatment Regimes from observational medical data. This framework is more flexible and adaptive for high dimensional action and state spaces than existing reinforcement learning methods to model real life complexity in heterogeneous disease progression and treatment choices, with the goal to provide doctor and patients the data-driven personalized decision recommendations. The proposed deep reinforcement learning framework contains a supervised learning step to predict the most possible expert actions; and a deep reinforcement learning step to estimate the long term value function of Dynamic Treatment Regimes...
August 2017: Healthcare Informatics: the Business Magazine for Information and Communication Systems
https://www.readbyqxmd.com/read/29424927/allogeneic-hematopoietic-stem-cell-transplantation-for-relapsed-follicular-lymphoma-a-combined-analysis-on-behalf-of-the-lymphoma-working-party-of-the-ebmt-and-the-lymphoma-committee-of-the-cibmtr
#5
Anna Sureda, Mei-Jie Zhang, Peter Dreger, Jeanette Carreras, Timothy Fenske, Herve Finel, Harry Schouten, Silvia Montoto, Stephen Robinson, Sonali M Smith, Ariane Boumedil, Mehdi Hamadani, Marcelo C Pasquini
BACKGROUND: Allogeneic hematopoietic stem cell transplantation (allo-HCT) remains the only potentially curative treatment option for relapsed follicular lymphoma (FL), yet questions remain about the optimal timing. This study analyzed long-term outcomes and associated factors among recipients of allo-HCT with FL. METHODS: Patients with relapsed FL who underwent allo-HCT from 2001 to 2011 with a human leukocyte antigen (HLA)-matched donor were included. Outcome analyses for overall survival (OS), progression-free survival (PFS), transplant-related mortality (TRM), and disease relapse/progression were calculated...
April 15, 2018: Cancer
https://www.readbyqxmd.com/read/29360515/choosing-wisely-bmt-american-society-for-blood-and-marrow-transplantation-and-canadian-blood-and-marrow-transplant-group-s-list-of-5-tests-and-treatments-to-question-in-blood-and-marrow-transplantation
#6
REVIEW
Sita Bhella, Navneet S Majhail, Jeffrey Betcher, Luciano J Costa, Andrew Daly, Christopher E Dandoy, Zachariah DeFilipp, Vi Doan, Alison Gulbis, Lisa Hicks, Mark Juckett, Nandita Khera, Amrita Krishnan, George Selby, Nirav N Shah, Melisa Stricherz, Auro Viswabandya, Christopher Bredeson, Matthew D Seftel
Choosing Wisely encourages dialogue about reducing unnecessary procedures, tests, or treatments in healthcare. The American Society for Blood and Marrow Transplantation (ASBMT) and Canadian Blood and Marrow Transplant Group (CBMTG) established a Choosing Wisely BMT Task Force whose objective was to create a list of top 5 practices in blood and marrow transplantation to be questioned. The Task Force consisted of representatives from ASBMT's Quality Outcomes, Education, and Practice Guidelines committees; ASBMT's Pharmacy Special Interest Group; CBMTG Program Directors; and Center for International Blood and Marrow Transplant Research (CIBMTR)...
January 31, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29343837/neurocognitive-dysfunction-in-hematopoietic-cell-transplant-recipients-expert-review-from-the-late-effects-and-quality-of-life-working-committee-of-the-cibmtr-and-complications-and-quality-of-life-working-party-of-the-ebmt
#7
REVIEW
David Buchbinder, Debra Lynch Kelly, Rafael F Duarte, Jeffery J Auletta, Neel Bhatt, Michael Byrne, Zachariah DeFilipp, Melissa Gabriel, Anuj Mahindra, Maxim Norkin, Helene Schoemans, Ami J Shah, Ibrahim Ahmed, Yoshiko Atsuta, Grzegorz W Basak, Sara Beattie, Sita Bhella, Christopher Bredeson, Nancy Bunin, Jignesh Dalal, Andrew Daly, James Gajewski, Robert Peter Gale, John Galvin, Mehdi Hamadani, Robert J Hayashi, Kehinde Adekola, Jason Law, Catherine J Lee, Jane Liesveld, Adriana K Malone, Arnon Nagler, Seema Naik, Taiga Nishihori, Susan K Parsons, Angela Scherwath, Hannah-Lise Schofield, Robert Soiffer, Jeff Szer, Ida Twist, Anne B Warwick, Baldeep M Wirk, Jean Yi, Minoo Battiwalla, Mary D E Flowers, Bipin Savani, Bronwen E Shaw
Hematopoietic cell transplantation (HCT) is a potentially curative treatment for children and adults with malignant and non-malignant diseases. Despite increasing survival rates, long-term morbidity following HCT is substantial. Neurocognitive dysfunction is a serious cause of morbidity, yet little is known about neurocognitive dysfunction following HCT. To address this gap, collaborative efforts of the Center for International Blood and Marrow Transplant Research and the European Society for Blood and Marrow Transplantation undertook an expert review of neurocognitive dysfunction following HCT...
January 17, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29242111/autologous-transplantation-in-follicular-lymphoma-with-early-therapy-failure-a-national-lymphocare-study-and-center-for-international-blood-and-marrow-transplant-research-analysis
#8
Carla Casulo, Jonathan W Friedberg, Kwang W Ahn, Christopher Flowers, Alyssa DiGilio, Sonali M Smith, Sairah Ahmed, David Inwards, Mahmoud Aljurf, Andy I Chen, Hannah Choe, Jonathon Cohen, Edward Copelan, Umar Farooq, Timothy S Fenske, Cesar Freytes, Sameh Gaballa, Siddhartha Ganguly, Yogesh Jethava, Rammurti T Kamble, Vaishalee P Kenkre, Hillard Lazarus, Aleksandr Lazaryan, Richard F Olsson, Andrew R Rezvani, David Rizzieri, Sachiko Seo, Gunjan L Shah, Nina Shah, Melham Solh, Anna Sureda, Basem William, Aaron Cumpston, Andrew D Zelenetz, Brian K Link, Mehdi Hamadani
Patients with follicular lymphoma (FL) experiencing early therapy failure (ETF) within 2 years of frontline chemoimmunotherapy have poor overall survival (OS). We analyzed data from the Center for International Blood and Marrow Transplant Research (CIBMTR) and the National LymphoCare Study (NLCS) to determine whether autologous hematopoietic cell transplant (autoHCT) can improve outcomes in this high-risk FL subgroup. ETF was defined as failure to achieve at least partial response after frontline chemoimmunotherapy or lymphoma progression within 2 years of frontline chemoimmunotherapy...
December 11, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29197676/intravenous-busulfan-compared-with-total-body-irradiation-pretransplant-conditioning-for-adults-with-acute-lymphoblastic-leukemia
#9
Partow Kebriaei, Claudio Anasetti, Mei-Jie Zhang, Hai-Lin Wang, Ibrahim Aldoss, Marcos de Lima, H Jean Khoury, Brenda M Sandmaier, Mary M Horowitz, Andrew Artz, Nelli Bejanyan, Stefan Ciurea, Hillard M Lazarus, Robert Peter Gale, Mark Litzow, Christopher Bredeson, Matthew D Seftel, Michael A Pulsipher, Jaap-Jan Boelens, Joseph Alvarnas, Richard Champlin, Stephen Forman, Vinod Pullarkat, Daniel Weisdorf, David I Marks
Total body irradiation (TBI) has been included in standard conditioning for acute lymphoblastic leukemia (ALL) before hematopoietic cell transplantation (HCT). Non-TBI regimens have incorporated busulfan (Bu) to decrease toxicity. This retrospective study analyzed TBI and Bu on outcomes of ALL patients 18-60 years old, in first or second complete remission (CR), undergoing HLA-compatible sibling, related, or unrelated donor HCT, who reported to the Center for International Blood and Marrow Transplant Research from 2005 to 2014...
December 25, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29079457/autologous-allogeneic-hematopoietic-cell-transplantation-versus-tandem-autologous-transplantation-for-multiple-myeloma-comparison-of-long-term-postrelapse-survival
#10
Myo Htut, Anita D'Souza, Amrita Krishnan, Benedetto Bruno, Mei-Jie Zhang, Mingwei Fei, Miguel Angel Diaz, Edward Copelan, Siddhartha Ganguly, Mehdi Hamadani, Mohamed Kharfan-Dabaja, Hillard Lazarus, Cindy Lee, Kenneth Meehan, Taiga Nishihori, Ayman Saad, Sachiko Seo, Muthalagu Ramanathan, Saad Z Usmani, Christina Gasparetto, Tomer M Mark, Yago Nieto, Parameswaran Hari
We compared postrelapse overall survival (OS) after autologous/allogeneic (auto/allo) versus tandem autologous (auto/auto) hematopoietic cell transplantation (HCT) in patients with multiple myeloma (MM). Postrelapse survival of patients receiving an auto/auto or auto/allo HCT for MM and prospectively reported to the Center for International Blood and Marrow Transplant Research between 2000 and 2010 were analyzed. Relapse occurred in 404 patients (72.4%) in the auto/auto group and in 178 patients (67.4%) in the auto/allo group after a median follow-up of 8...
March 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29032274/assessment-of-impact-of-hla-type-on-outcomes-of-allogeneic-hematopoietic-stem-cell-transplantation-for-chronic-lymphocytic-leukemia
#11
Brian T Hill, Kwang Woo Ahn, Zhen-Huan Hu, Mahmoud Aljurf, Amer Beitinjaneh, Jean-Yves Cahn, Jan Cerny, Mohamed A Kharfan-Dabaja, Siddhartha Ganguly, Nilanjan Ghosh, Michael R Grunwald, Yoshihiro Inamoto, Tamila Kindwall-Keller, Taiga Nishihori, Richard F Olsson, Ayman Saad, Matthew Seftel, Sachiko Seo, Jeffrey Szer, Martin Tallman, Celalettin Ustun, Peter H Wiernik, Richard T Maziarz, Matt Kalaycio, Edwin Alyea, Uday Popat, Ronald Sobecks, Wael Saber
Chronic lymphocytic leukemia (CLL) is a common hematologic malignancy with many highly effective therapies. Chemorefractory disease, often characterized by deletion of chromosome 17p, has historically been associated with very poor outcomes, leading to the application of allogeneic hematopoietic stem cell transplantation (allo-HCT) for medically fit patients. Although the use of allo-HCT has declined since the introduction of novel targeted therapy for the treatment of CLL, there remains significant interest in understanding factors that may influence the efficacy of allo-HCT, the only known curative treatment for CLL...
March 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29032272/fludarabine-and-busulfan-versus-fludarabine-cyclophosphamide-and-rituximab-as-reduced-intensity-conditioning-for-allogeneic-transplantation-in-follicular-lymphoma
#12
Narendranath Epperla, Kwang Woo Ahn, Philippe Armand, Samantha Jaglowski, Sairah Ahmed, Vaishalee P Kenkre, Bipin Savani, Madan Jagasia, Nirav N Shah, Timothy S Fenske, Anna Sureda, Sonali M Smith, Mehdi Hamadani
Large, multicenter studies comparing commonly used reduced-intensity conditioning (RIC) approaches in follicular lymphoma (FL) have not been performed. Using the Center for International Blood and Marrow Transplant Research database, we report the outcomes of the 2 most commonly used RIC approaches, fludarabine and busulfan (Flu/Bu) versus fludarabine, cyclophosphamide, and rituximab (FCR) in FL patients. We evaluated 200 FL patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) who received RIC with either Flu/Bu (n = 98) or FCR (n = 102) during 2008 to 2014...
January 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28945102/survival-after-stem-cell-transplant-in-pediatric-and-young-adult-patients-with-relapsed-and-refractory-b-cell-acute-lymphoblastic-leukemia
#13
Alessandro Crotta, Jie Zhang, Christopher Keir
OBJECTIVE: Allogeneic stem-cell transplant (allo-SCT) is the standard of care for pediatric patients with acute lymphoblastic leukemia (ALL) who relapse after frontline chemotherapy; however, for patients who relapse after allo-SCT, outcomes are very poor. Few studies have examined overall survival in this patient population, particularly in patients who received a second allo-SCT. METHODS: This was a retrospective analysis using data from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry...
March 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28939455/neurocognitive-dysfunction-in-hematopoietic-cell-transplant-recipients-expert-review-from-the-late-effects-and-quality-of-life-working-committee-of-the-center-for-international-blood-and-marrow-transplant-research-and-complications-and-quality-of-life-working
#14
REVIEW
Debra Lynch Kelly, David Buchbinder, Rafael F Duarte, Jeffrey J Auletta, Neel Bhatt, Michael Byrne, Zachariah DeFilipp, Melissa Gabriel, Anuj Mahindra, Maxim Norkin, Helene Schoemans, Ami J Shah, Ibrahim Ahmed, Yoshiko Atsuta, Grzegorz W Basak, Sara Beattie, Sita Bhella, Christopher Bredeson, Nancy Bunin, Jignesh Dalal, Andrew Daly, James Gajewski, Robert Peter Gale, John Galvin, Mehdi Hamadani, Robert J Hayashi, Kehinde Adekola, Jason Law, Catherine J Lee, Jane Liesveld, Adriana K Malone, Arnon Nagler, Seema Naik, Taiga Nishihori, Susan K Parsons, Angela Scherwath, Hannah-Lise Schofield, Robert Soiffer, Jeff Szer, Ida Twist, Anne Warwick, Baldeep M Wirk, Jean Yi, Minoo Battiwalla, Mary E Flowers, Bipin Savani, Bronwen E Shaw
Hematopoietic cell transplantation (HCT) is a potentially curative treatment for children and adults with malignant and nonmalignant diseases. Despite increasing survival rates, long-term morbidity after HCT is substantial. Neurocognitive dysfunction is a serious cause of morbidity, yet little is known about neurocognitive dysfunction after HCT. To address this gap, collaborative efforts of the Center for International Blood and Marrow Transplant Research and the European Society for Blood and Marrow Transplantation undertook an expert review of neurocognitive dysfunction after HCT...
February 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28869618/outcomes-following-autologous-hematopoietic-stem-cell-transplant-for-patients-with-relapsed-wilms-tumor-a-cibmtr-retrospective-analysis
#15
M H Malogolowkin, M T Hemmer, J Le-Rademacher, G A Hale, P A Mehta, A R Smith, C Kitko, A Abraham, H Abdel-Azim, C Dandoy, M Angel Diaz, R P Gale, G Guilcher, R Hayashi, S Jodele, K A Kasow, M L MacMillian, M Thakar, B M Wirk, A Woolfrey, E L Thiel
Despite the marked improvement in the overall survival (OS) for patients diagnosed with Wilms' tumor (WT), the outcomes for those who experience relapse have remained disappointing. We describe the outcomes of 253 patients with relapsed WT who received high-dose chemotherapy (HDT) followed by autologous hematopoietic stem cell transplant (HCT) between 1990 and 2013, and were reported to the Center for International Blood and Marrow Transplantation Research. The 5-year estimates for event-free survival (EFS) and OS were 36% (95% confidence interval (CI); 29-43%) and 45% (95 CI; 38-51%), respectively...
November 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28865971/haploidentical-hematopoietic-stem-cell-transplantation-for-myelodysplastic-syndrome
#16
Xiao-Dong Mo, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Chen-Hua Yan, Huan Chen, Yu-Hong Chen, Wei Han, Feng-Rong Wang, Jing-Zhi Wang, Kai-Yan Liu, Xiao-Jun Huang
This study aimed to validate the capability of the Center for International Blood and Marrow Transplant Research (CIBMTR) prognostic scoring system to predict outcomes of patients with myelodysplastic syndromes (MDS) who had undergone HLA-haploidentical related donor hematopoietic stem cell transplantation (haplo-HSCT). We also propose and validate a more suitable prognostic scoring system. A total of 157 patients with MDS who underwent haplo-HSCT were enrolled. The CIBMTR prognostic scoring system could predict the 2-year clinical outcomes, but failed to predict the 100-day clinical outcomes after haplo-HSCT...
December 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28817182/centralized-patient-reported-outcome-data-collection-in-transplantation-is-feasible-and-clinically-meaningful
#17
Bronwen E Shaw, Ruta Brazauskas, Heather R Millard, Rachel Fonstad, Kathryn E Flynn, Amy Abernethy, Jenny Vogel, Charney Petroske, Deborah Mattila, Rebecca Drexler, Stephanie J Lee, Mary M Horowitz, J Douglas Rizzo
BACKGROUND: Allogeneic hematopoietic cell transplantation (HCT) cures many patients, but often with the risk of late effects and impaired quality of life. The value of quantifying patient-reported outcomes (PROs) is increasingly being recognized, but the routine collection of PROs is uncommon. This study evaluated the feasibility of prospective PRO collection by an outcome registry at multiple time points from unselected HCT patients undergoing transplantation at centers contributing clinical data to the Center for International Blood and Marrow Transplant Research (CIBMTR), and then it correlated the PRO data with clinical and demographic data...
December 1, 2017: Cancer
https://www.readbyqxmd.com/read/28811306/replication-and-validation-of-genetic-polymorphisms-associated-with-survival-after-allogeneic-blood-or-marrow-transplant
#18
Ezgi Karaesmen, Abbas A Rizvi, Leah M Preus, Philip L McCarthy, Marcelo C Pasquini, Kenan Onel, Xiaochun Zhu, Stephen Spellman, Christopher A Haiman, Daniel O Stram, Loreall Pooler, Xin Sheng, Qianqian Zhu, Li Yan, Qian Liu, Qiang Hu, Amy Webb, Guy Brock, Alyssa I Clay-Gilmour, Sebastiano Battaglia, David Tritchler, Song Liu, Theresa Hahn, Lara E Sucheston-Campbell
Multiple candidate gene-association studies of non-HLA single-nucleotide polymorphisms (SNPs) and outcomes after blood or marrow transplant (BMT) have been conducted. We identified 70 publications reporting 45 SNPs in 36 genes significantly associated with disease-related mortality, progression-free survival, transplant-related mortality, and/or overall survival after BMT. Replication and validation of these SNP associations were performed using DISCOVeRY-BMT (Determining the Influence of Susceptibility COnveying Variants Related to one-Year mortality after BMT), a well-powered genome-wide association study consisting of 2 cohorts, totaling 2888 BMT recipients with acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome, and their HLA-matched unrelated donors, reported to the Center for International Blood and Marrow Transplant Research...
September 28, 2017: Blood
https://www.readbyqxmd.com/read/28674027/increasing-use-of-allogeneic-hematopoietic-cell-transplantation-in-patients-aged-70-years-and-older-in-the-united-states
#19
Lori Muffly, Marcelo C Pasquini, Michael Martens, Ruta Brazauskas, Xiaochun Zhu, Kehinde Adekola, Mahmoud Aljurf, Karen K Ballen, Ashish Bajel, Frederic Baron, Minoo Battiwalla, Amer Beitinjaneh, Jean-Yves Cahn, Mathew Carabasi, Yi-Bin Chen, Saurabh Chhabra, Stefan Ciurea, Edward Copelan, Anita D'Souza, John Edwards, James Foran, Cesar O Freytes, Henry C Fung, Robert Peter Gale, Sergio Giralt, Shahrukh K Hashmi, Gerhard C Hildebrandt, Vincent Ho, Ann Jakubowski, Hillard Lazarus, Marlise R Luskin, Rodrigo Martino, Richard Maziarz, Philip McCarthy, Taiga Nishihori, Rebecca Olin, Richard F Olsson, Attaphol Pawarode, Edward Peres, Andrew R Rezvani, David Rizzieri, Bipin N Savani, Harry C Schouten, Mitchell Sabloff, Matthew Seftel, Sachiko Seo, Mohamed L Sorror, Jeff Szer, Baldeep M Wirk, William A Wood, Andrew Artz
In this study, we evaluated trends and outcomes of allogeneic hematopoietic cell transplantation (HCT) in adults ≥70 years with hematologic malignancies across the United States. Adults ≥70 years with a hematologic malignancy undergoing first allogeneic HCT in the United States between 2000 and 2013 and reported to the Center for International Blood and Marrow Transplant Research were eligible. Transplant utilization and transplant outcomes, including overall survival (OS), progression-free survival (PFS), and transplant-related mortality (TRM) were studied...
August 31, 2017: Blood
https://www.readbyqxmd.com/read/28606646/current-use-and-trends-in-hematopoietic-cell-transplantation-in-the-united-states
#20
EDITORIAL
Anita D'Souza, Stephanie Lee, Xiaochun Zhu, Marcelo Pasquini
Hematopoietic Cell Transplantation (HCT) is an established curative treatment for a number of malignant and nonmalignant diseases involving the hematopoietic system and some solid tumors. In this report, we provide information about the number of HCT procedures performed in the United States in 2015, and analyze trends and outcomes of HCT as reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). We show that the number of HCTs performed annually continues to increase, as the indications for HCT, preferred donor sources, and graft-versus-host prophylaxis continue to evolve...
September 2017: Biology of Blood and Marrow Transplantation
keyword
keyword
115199
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"